Dupilumab Phase 4 Study

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT03411837
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — BIOLOGICAL
    Biologic (monoclonal antibody)

Study Details

The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.

Key Dates

First listed
Jan 26, 2018
Start date
Oct 16, 2017
Status verified
Oct 2021
Primary completion
Aug 31, 2019
Completion
Aug 31, 2019

Study Design

Enrollment
46 participants (actual)

Arms

  • Arm: Dupilumab
    Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care

Primary Outcome Measure

Quantified Itch Survey [ Time Frame: 1 to 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern University Department of DermatologyChicagoIllinois60611-

Find similar trials in Chicago, IL

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials
By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Northwestern University Department of Dermatology· Chicago, IL

Related Studies